Jeffreys Henry advise Poolbeg Pharma Plc on £50m AIM IPO

Jeffreys Henry, the award-winning provider of audit, tax and advisory services to LSE, AIM and Aquis listed companies, has recently advised Poolbeg Pharma Plc, a pharmaceutical company, on its £50 million IPO on the AIM market of the London Stock Exchange.

Poolbeg Pharma, a spin out of Open Orphan, has successfully raised £25 million (before expenses) and lists with a market capitalisation of £50 million.

Poolbeg Pharma is a clinical-stage infectious disease pharmaceutical company. Their novel capital light clinical model enables them to develop multiple products faster and more cost effectively than the traditional biotech model.

Chief executive Jeremy Skillington said: “The IPO and funds raised have provided a strong platform to begin our rapid growth plan. With experienced management on board and the exciting assets acquired from Open Orphan, we look forward to delivering value to our shareholder base and generating innovation in the previously overlooked infectious disease space which is now one of the fastest growing markets and is expected to exceed $250bn by 2025.”

Jeffreys Henry acted as the Reporting Accountant in respect of the IPO.

FURTHER INFORMATION

NICK MICHAELS

Partner - Capital Markets

Throughout his career, Nick has extensively worked with public listed companies, including those listed on the LSE Standard List, AIM, Aquis (NEX) and CSE listed companies, during a time of accelerated growth, reverse takeovers and mergers and acquisitions.

SANJAY PARMAR

Partner - Capital Markets

Sanjay qualified as a Chartered Accountant in 1990. He is a corporate specialist with a client base in various sectors. Sanjay is the lead auditor on over 21 of our listed companies and has acted as the Reporting Accountant on a number of IPO’s and reverse transactions. He has extensive experience in the application of International Financial Reporting Standards (“IFRS”) and undertaking investigating accountant assignments on acquisitions.